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Background-—Studies assessing the differential impact of sex on outcomes of aortic valve replacement (AVR) yielded conflicting
results. We sought to investigate sex-related differences in AVR utilization, patient risk profile, and in-hospital outcomes using the
Nationwide Inpatient Sample.
Methods and Results-—In total, 166 809 patients (63% male and 37% female) who underwent AVR between 2003 and 2014 were
identified, and 48.5% had a concomitant cardiac surgery procedure. Compared with men, women were older and had more
nonatherosclerotic comorbid conditions including hypertension, diabetes mellitus, obstructive pulmonary disease, atrial
fibrillation/flutter, and anemia but fewer incidences of coronary and peripheral arterial disease and prior sternotomies. In-
hospital mortality was significantly higher in women (5.6% versus 4%, P<0.001). Propensity matching was performed to assess the
impact of sex on the outcomes of isolated AVR and yielded 28 237 matched pairs of male and female participants. In the
propensity-matched groups, in-hospital mortality was higher in women (3.3% versus 2.9%, P<0.001). Along with vascular
complications and blood transfusion (6% versus 5.6%, P=0.027 and 40.4% versus 33.9%, P<0.001, respectively). Rates of stroke,
permanent pacemaker implantation, and acute kidney injury requiring dialysis were similar (2.4% versus 2.4%, P=0.99; 6% versus
6.3%, P=0.15; and 1.4% versus 1.3%, P=0.14, respectively). Length of stay median and interquartile range were both similar
between groups (76 days). Rates of nonhome discharge were higher among women (27.9% versus 19.6%, P<0.001).
Conclusions-—Women have worse in-hospital mortality following AVR compared with men. Coupled with the accumulating
evidence suggesting higher magnitude of benefit of transcatheter AVR over AVR in women, women should perhaps be offered
transcatheter AVR over AVR at a lower threshold than men. ( J Am Heart Assoc. 2017;6:e006370. DOI: 10.1161/JAHA.117.
006370.)
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S ex-related differences in the incidence, pathophysiology,presentation, treatment, and outcomes of cardiovascular
diseases including aortic stenosis (AS) have been studied
extensively.1 Aortic valve replacement (AVR) has historically
been the gold standard treatment of calcific AS.2 The
outcomes of AVR have improved significantly nationwide in
the past decade.3 Several studies have assessed the differ-
ential impact of sex on outcomes of AVR but yielded
conflicting results.4–13 The interest in examining the sex gap
in AS patients has been renewed with the introduction and
widespread adoption of transcatheter AVR (TAVR). Recently, a
report from the American College of Cardiology (ACC) and TVT
registry and a large meta-analysis showed superior outcomes
with TAVR in women compared with men.1,14 We hypothe-
sized that female patients have worse outcomes following
AVR compared with propensity-matched male patients. We
propose that if our hypothesis is true, perhaps women should
be offered TAVR over surgical AVR at a lower threshold
compared with men, given the mounting evidence of better
outcomes of TAVR in women versus men.
We aimed to utilize a large national database to investigate
(1) trends of AVR utilization in women versus men over a 12-
year period, (2) sex differences in risk profile of patients
undergoing AVR, (3) in-hospital morbidity and mortality of AVR
in men versus women and (4) the trends of these outcomes
over time.
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Methods
Study Data
The Nationwide Inpatient Sample (NIS) was used to derive
patient-relevant information between January 2003 and
December 2014. The NIS is the largest publicly available all-
payer administrative claims–based database and contains
information about patient discharges from 1000 nonfederal
hospitals in 45 states. It contains clinical and resource
utilization information on 5 million to 8 million discharges
annually, with safeguards to protect the privacy of individual
patients, physicians, and hospitals. These data are stratified
to represent 20% of US inpatient hospitalizations across
different hospital and geographic regions (random sample).
National estimates of the entire US hospitalized population
were calculated using the Agency for Healthcare Research
and Quality sampling and weighting method.
Study Population
Patients with a discharge diagnosis of aortic valve stenosis
(International Classification of Diseases, Ninth Revision, Clin-
ical Modification [ICD-9-CM] codes 424.1, 395.0, 395.2,
396.2, 746.3) who underwent AVR (ICD-9-CM procedure code
35.20 and 35.21) during the study period were identified from
the NIS database.
Trends of Utilization and Outcomes of AVR
The trend of surgical AVR during the 12-year study period
were assessed using weighted values (national estimates).
The Mann–Kendall test was used to evaluate trends of AVR in
male and female patients. Baseline comorbidities were
described, and in-hospital morbidity and mortality were
assessed and compared between sexes.
Comparative Outcomes Analysis
To account for potential confounding factors and to reduce
the effect of selection bias, a propensity score–matching
model was developed using logistic regression to derive 2
matched groups for comparative outcomes analysis. After
excluding patients who underwent concomitant cardiac
surgery, patients who underwent “isolated” AVR were entered
into a nearest neighbor 1:1 variable ratio, parallel, balanced
propensity score–matching model using a caliper of 0.01 to
ensure perfect matching. Table S1 lists all covariates that we
included in the propensity score models. We performed
multiple imputations to impute missing values for race
(missing in 16% of observations) using the fully conditional
specification method (an iterative Markov chain Monte Carlo
algorithm) using age, sex, insurance status, comorbid condi-
tions, hospital region, and clinical characteristics. This method
adheres to the recommendations provided by the Healthcare
Cost and Utilization Project (HCUP)15 for handling missing
racial data. To estimate the cost of hospitalization, the NIS
data were merged with cost-to-charge ratios available from
the HCUP. We estimated the cost of each inpatient stay by
multiplying the total hospital charge with cost-to-charge
ratios.
The primary end point was in-hospital death. Secondary
outcomes included procedural mortality (defined as death
occurring on the same hospital day as AVR), vascular
complications, pacemaker implantation, transient ischemic
attack, stroke, blood transfusion, acute kidney injury requiring
dialysis, cardiac tamponade, hospital length of stay, cost of
hospitalization, and discharge disposition. Subgroup analyses
were performed for the outcomes of in-hospital mortality in
the propensity score–matched groups to assess the impact of
age, age, race, teaching status, and primary and selected
relevant major comorbidities on the differences in mortality
between male and female participants.
Statistical Analyses
Descriptive statistics are presented as frequencies with
percentages for categorical variables. Mean, standard devia-
tion, median, and interquartile range were reported for
continuous measures. Baseline characteristics were com-
pared using a Pearson v2 test and Fisher exact test for
categorical variables and an independent-samples t test for
continuous variables. Trend weights accounting for changes in
the NIS sampling design are available only for data between
1998 and 2011. For 2012 and 2013, trend weights were not
available, and the standard survey weights were used.
Matched categorical variables were presented as frequencies
with percentages and compared using the McNemar test.
Matched continuous variables were presented as means with
standard deviations and compared using a paired-samples
Clinical Perspective
What Is New?
• In a large contemporary US database, women underwent
aortic valve replacement for aortic stenosis less than men.
• Aortic valve replacement in women was associated with
worse in-hospital mortality and higher cost compared with
men.
What Are the Clinical Implications?
• Women had worse outcomes with aortic valve replacement
compared with men, and this was consistent over 12 years.
• These data should be considered when assessing suitability
of women for transcatheter or surgical aortic valve replace-
ment.
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t test. A type I error rate of <0.05 was considered statistically
significant. All statistical analyses were performed using SPSS
version 24 (IBM Corp) and R, version 3.3.1 (R Foundation for
Statistical Computing).
Results
In total, 166 809 patients underwent AVR between 2003 and
2014 (weighted national estimates: 825 721 patients), of
whom 105 106 (63%) were male and 61 703 (37%) were
female. The utilization disparity in AVR was constant
throughout the study period (Figure 1). Baseline characteristic
profiles were distinctly different between men and women, as
detailed in Table 1. Compared with men, women were older
(7013 versus 6714 years, P<0.001) and had higher rates
of hypertension, diabetes mellitus, chronic obstructive lung
disease, and anemia. In contrast, coronary and peripheral
arterial disease and history of prior sternotomy were more
prevalent in men. The majority of AVRs (67.4%) were
performed at teaching hospitals, and 32.8% were performed
during an unplanned admission. More women had Medicare/
Medicaid insurance compared with men (75.4% versus 63.6%,
P<0.001). Bioprosthetic valve utilization increased from 46%
in 2003 to 65% in 2014, and this upward trend was similar for
men and women (Figure 1). Concomitant cardiac surgery was
common (48.5%); men were more likely to undergo simulta-
neous coronary artery bypass grafting (42.8% versus 33.6%,
P<0.001), whereas women were more likely to undergo
simultaneous mitral valve replacement (8.7% versus 4.8%,
P<0.001). In-hospital mortality was significantly higher in
women than in men (5.6% versus 4%, P<0.001; Table 2).
Women had higher rates of vascular complications (5.8%
versus 5.5%, P<0.001), permanent pacemaker implantation
(7.2% versus 6.6%, P<0.001), and blood transfusion (40.9%
versus 35.4%, P<0.001). Rates of stroke were similar in men
and women (2.7% versus 2.9%, P=0.096).
Outcomes of Isolated AVR
Among the 166 809 patients who underwent AVR during the
study period, 85 975 (51.5%) had isolated AVR. The majority
of these patients (60.8%) were men. Baseline characteristics
and in-hospital outcomes of the unmatched groups of men
and women who underwent isolated AVR are shown in Tables
S2 and S3. Propensity score matching yielded 28 237
matched pairs of male and female patients who underwent
isolated AVR (Figure 2). Variables used in propensity match-
ing are listed in Table S1. Baseline characteristics were well
matched between groups (Table 3, Figure S1). After propen-
sity matching, in-hospital mortality remained significantly
higher in women than in men (3.3% versus 2.9%, P=0.001;
Table 4). Although in-hospital mortality decreased among
both men and women over time, the significant gap between
men and women remained constant throughout the study
period (Figure 3). Vascular complications and blood transfu-
sions were more frequent in female than male patients (6%
versus 5.6%, P=0.027; and 40.4% versus 33.9%, P<0.001,
respectively; Table 4). Rates of stroke, permanent pacemaker
implantation, and acute kidney injury requiring dialysis were
similar in male and female patients (2.4% versus 2.4%,
P=0.99; 6.1% versus 6.3%, P=0.36; and 1.4% versus 1.3%,
P=0.14, respectively). Length of stay was longer for women
(10.19.6 versus 9.69 days, P<0.001), and rates of non-
home discharge (skilled nursing facility, nursing home, or
intermediate care) were higher for women (27.9% versus
19.6%, P<0.001). Cost of hospitalization was similar for
the 2 groups ($50 11124 372 for women versus
$49 77434 701 for men, P=0.248).
Figure 1. Utilization trends of surgical aortic valve replacement in men and women between 2003 and
2014. AVR indicates aortic valve replacement.
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Table 1. Characteristics of Patients Undergoing Surgical AVR Between 2003 and 2014 (Including Combined Procedures)
Characteristic All Patients (n=166 809) Male (n=105 106) Female (n=61 703) P Value
Age, y, mean (SD) 68 (14) 67 (14) 70 (13) <0.0001
Race, n (%) <0.0001
White 139 714 (83.8) 87 946 (83.7) 51 768 (83.9)
Black 8516 (5.1) 5186 (4.9) 3330 (5.4)
Hispanic 10 084 (6) 6745 (6.4) 3339 (5.4)
Medical comorbidity, n (%)
Hypertension 106 535 (63.9) 66 374 (63.1) 40 161 (65.1) <0.0001
Diabetes mellitus 42 900 (25.7) 26 503 (25.2) 16 397 (26.6) <0.0001
Prior sternotomy 7195 (4.3) 5592 (5.3) 1603 (2.6) <0.0001
Chronic pulmonary disease 33 513 (20.1) 20 342 (19.4) 13 171 (21.3) <0.0001
Atrial fibrillation/flutter 72 999 (43.8) 45 971 (43.7) 27 028 (43.8) 0.794
Cardiogenic shock 6565 (3.9) 4051 (3.9) 2514 (4.1) 0.026
Anemia 30 713 (18.4) 18 366 (17.5) 12 347 (20) <0.0001
Coagulopathy 39 755 (23.8) 25 040 (23.8) 14 715 (23.8) 0.91
Conduction abnormalities 5438 (3.3) 3578 (3.4) 1860 (3) <0.0001
Peripheral vascular disease 29 535 (17.7) 20 115 (19.1) 9420 (15.3) <0.0001
Chronic renal disease 21 029 (12.6) 14 239 (13.5) 6790 (11) <0.0001
Coronary artery disease 82 622 (49.5) 55 339 (52.7) 27 283 (44.2) <0.0001
Metastatic cancer 293 (0.2) 207 (0.2) 86 (0.1) 0.007
Liver disease 2542 (1.5) 1740 (1.7) 802 (1.3) <0.0001
Aortic prosthesis
Bioprosthetic 100 999 (60.50) 63 399 (60.3) 37 600 (60.9) 0.013
Mechanical 66 005 (39.6) 41 816 (39.8) 24 189 (39.2) 0.019
Concomitant procedures, n (%)
Coronary artery bypass 65 781 (39.4) 44 960 (42.8) 20 821 (33.7) <0.0001
Percutaneous coronary intervention 699 (0.4) 461 (0.4) 238 (0.4) 0.106
Mitral valve valvuloplasty 5278 (3.2) 3406 (3.2) 1872 (3) 0.02
Mitral valve replacement 10 441 (6.3) 5050 (4.8) 5391 (8.7) <0.0001
Annuloplasty 5278 (3.2) 3406 (3.2) 1872 (3) 0.02
Open ASD\VSD repair 3403 (2) 2108 (2) 1295 (2.1) 0.194
IABP/LV assist device use 7462 (4.5) 4905 (4.7) 2557 (4.1) <0.0001
Hospital characteristics, n (%)
Teaching hospital 112 372 (67.4) 71 079 (67.6) 41 293 (66.9) 0.003
Hospital bed size 0.074
Small 11 249 (6.7) 6993 (6.7) 4256 (6.9)
Medium 30 336 (18.2) 19 226 (18.3) 11 110 (18)
Large 125 224 (75.1) 78 887 (75.1) 46 337 (75.1)
Rural location 5924 (3.6) 3782 (3.6) 2142 (3.5) 0.177
Nonelective admission status, n (%) 54 717 (32.8) 34 718 (33) 19 999 (32.4) 0.009
Continued
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A subgroup analysis of the propensity score–matched
cohorts showed that the differential impact of sex on in-
hospital mortality was consistent among subcohorts of
patients stratified based on age (<65 versus >65 years);
hospital teaching status; race; insurance status; and the
presence of diabetes mellitus, peripheral vascular disease, or
atrial fibrillation (Figure S2).
Sensitivity Analysis
To further assess for residual confounding, a rule-out approach
to sensitivity analysiswas used to illustrate howstrongly a single
unmeasured confounder would need to be associated with
female sex and a significant outcome end point to fully explain
our findings (Figure S3).16 To fully explain the observed
difference in blood transfusion rates between male and female
patients undergoing AVR, a confounderwould have to be 2 times
more likely to be associated with female than male sex and,
concurrently, increase the risk of blood transfusion by 6 times.
Discussion
The major findings of the current investigations are as follows.
First, men undergo surgical AVR for AS more than women,
Table 1. Continued
Characteristic All Patients (n=166 809) Male (n=105 106) Female (n=61 703) P Value
Primary payer, n (%) <0.0001
Medicare/Medicaid 113 333 (67.9) 66 835 (63.6) 46 498 (75.4)
Private including HMO 46 358 (27.8) 33 143 (31.5) 13 215 (21.4)
Self-pay/no charge/other 7118 (4.3) 5128 (4.9) 1990 (3.2)
Median household income, n (%) <0.0001
0 to 25th percentiles 35 947 (21.5) 21 889 (20.8) 14 058 (22.8)
26th to 50th percentiles 43 307 (26) 26 958 (25.6) 16 349 (26.5)
51st to 75th percentiles 43 431 (26) 27 572 (26.2) 15 859 (25.7)
76th to 100th percentiles 44 124 (26.5) 28 687 (27.3) 15 437 (25)
ASD indicates atrial septal defect; AVR, aortic valve replacement; HMO, health maintenance organization; IABP, intra-aortic balloon pump; LV, left ventricular; VSD, ventricular septal defect.
Table 2. In-Hospital Outcomes of Patients Undergoing Surgical AVR Between 2003 and 2014 (Including Combined Procedures)
All Patients (n=166 809) Male (n=105 106) Female (n=61 703) P Value
Clinical outcome, n (%)
In-hospital death 7591 (4.6) 4165 (4) 3426 (5.6) <0.0001
Procedural death 947 (0.6) 493 (0.5) 454 (0.7) <0.0001
Vascular complications 9392 (5.6) 5815 (5.5) 3577 (5.8) 0.024
Vascular complications requiring surgery 6810 (4.1) 4344 (4.1) 2466 (4) 0.174
Permanent pacemaker implantation 11 453 (6.9) 6980 (6.6) 4473 (7.2) <0.0001
Transient ischemic attack 570 (0.3) 345 (0.3) 225 (0.4) 0.219
Clinical stroke 4634 (2.8) 2866 (2.7) 1768 (2.9) 0.096
Acute kidney injury 26 264 (15.7) 17 432 (16.6) 8832 (14.3) <0.0001
Acute kidney injury requiring dialysis 2934 (1.8) 1811 (1.7) 1123 (1.8) 0.146
Blood transfusion 62 473 (37.5) 37 254 (35.4) 25 219 (40.9) <0.0001
Cardiac tamponade 1512 (0.9) 985 (0.9) 527 (0.9) 0.084
Discharge status, n (%) <0.0001
Discharged home 114 714 (68.8) 77 727 (74) 36 987 (59.9)
Discharged SNF/NH/IC 44 134 (26.5) 22 996 (21.9) 21 138 (34.3)
Length of stay, d, median (IQR) 8 (7) 8 (7) 8 (8) <0.0001
Cost of hospitalization, $, mean (SD) 56 260 (41 280) 55 834 (40 937) 56 985 (41 849) <0.0001
AVR indicates aortic valve replacement; IC, intermediate care; IQR, interquartile range; NH, nursing home; SNF, skilled nursing facility.
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Second, women who underwent AVR in the United States
between 2003 and 2014 were older and had distinctive risk
profiles and demographics compared with men. Third, women
had higher unadjusted and adjusted in-hospital mortality
following AVR than men, and this was consistent over time.
Fourth, after risk adjustment, women had more vascular
complications and blood transfusions than men and were
more likely to be discharged to a skilled nursing facility,
nursing home, or intermediate care center.
The higher utilization of AVR in men compared with
women in this study (63% versus 37%, P<0.001) is
consistent with previous studies.17–19 Several plausible
explanations can be postulated from the existing literature.
Regarding disparity in the incidence of AS, historical
echocardiographic data showed that the risk of developing
AS was 2-fold higher in men than in women20; however,
nationwide claim-based studies in hospitalized patients
showed a less pronounced disparity in AS diagnosis between
men and women. Among 113 847 patients admitted with an
aortic valve disorder diagnosis in the United States, 55.1%
were men.21 A similar study in Sweden showed that men
constituted 52% of all patients newly diagnosed with AS.22
Even a lower incidence of new AS diagnosis in men was
observed in a large Scottish registry of 19 733 patients, of
whom 46.8% were men.23 Regarding disparity in referral for
testing, women with AS were less likely to be seen by a
specialist and less likely to be referred for testing.19
Regarding disparity in referral to surgery, women diagnosed
with AS had unfavorable preoperative baseline
characteristics compared with men at the time of presen-
tation and thus were less likely to be referred to surgical
treatment.4,9,24 Interestingly, this disparity in referral to valve
replacement is not seen with the current TAVR practice; in
the United States and Germany, women composed 52% and
55%, respectively, of all patients undergoing TAVR, respec-
tively.25,26 Furthermore, compared with women, men had
much higher prevalence of coronary artery disease (52.7%
versus 44.2%, P<0.001) and were more likely to undergo
coronary artery bypass grafting (42.8% versus 33.7%,
P<0.001). Although speculative, perhaps many men under-
went AVR for lesser degrees of aortic valve disease at the
time of coronary bypass, contributing to the larger number
of men undergoing AVR overall. The disparity of AVR
utilization in women seems to be more pronounced in the
most recent year (Figure 1). This could be related to the
introduction of TAVR. Since TAVR became commercially
available in the United States in 2011, women have been
referred more often to TAVR versus AVR compared with men
(Figure S4). This may explain the later divergence of
utilization trends of AVR between men and women (Fig-
ure 1).
In line with the majority of previous studies, we found
distinctive risk profiles for men and women undergoing
AVR.4,6,11,12,17,27 Women undergoing AVR (isolated or com-
bined) were older and had more nonatherosclerotic comorbid
conditions at presentation including hypertension, diabetes
mellitus, chronic obstructive pulmonary disease, atrial fibril-
lation/flutter, and anemia compared with men. In contrast,
men presented with higher incidences of coronary and
peripheral arterial disease and prior sternotomies. The impact
of sex on the pathophysiology of valvular heart disease has
not been studied extensively. In addition, the focus of
research on this topic has been to investigate sex differences
in ventricular responses to pressure and volume overload
posed by valvular disease rather than evaluating differences in
the mechanism of AS itself.28 Nevertheless, 3 recent studies
found important differences between men and women with
regard to the development, extent, and progression of aortic
valve calcifications supporting sex-related differences in the
mechanism of AS.29–31 Our findings of distinct risk profiles
between men and women with AS at a community level
support this notion and call for further research in sex-specific
disease mechanisms.
To date, there is no contemporary large-scale study
assessing sex-related differences in clinical outcomes follow-
ing AVR. Evidence from the available series conflicts with
older studies showing no difference in post-AVR mortality
between men and women and more contemporary studies
showing worse short- and long-term outcomes in women
compared with men (Table S4). In this real-world study of
166 809 patients, in-hospital mortality was significantly
Figure 2. Study flow chart. NE indicates national estimate.
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Table 3. Characteristics of Propensity Score–Matched Patients Undergoing Isolated Surgical AVR Between 2003 and 2014
Characteristic Male (n=28 237) Female (n=28 237) P Value
Age, y, mean (SD) 68 (13.3) 68 (14.1) 0.561
Race, n (%) 0.988
White 23 721 (84) 23 732 (84)
Black 1475 (5.2) 1469 (5.2)
Hispanic 1591 (5.6) 1560 (5.5)
Medical comorbidity, n (%)
Hypertension 18 255 (64.6) 18 278 (64.7) 0.846
Diabetes mellitus 6757 (23.9) 6774 (24) 0.874
Prior sternotomy 1017 (3.6) 960 (3.4) 0.262
Chronic pulmonary disease 5713 (20.2) 5708 (20.2) 0.966
Atrial fibrillation/flutter 11 429 (40.5) 11 537 (40.9) 0.354
Cardiogenic shock 716 (2.5) 687 (2.4) 0.45
Anemia 5259 (18.6) 5293 (18.7) 0.72
Coagulopathy 6166 (21.8) 6136 (21.7) 0.767
Conduction abnormalities 936 (3.3) 924 (3.3) 0.796
Peripheral vascular disease 4586 (16.2) 4634 (16.4) 0.586
Chronic renal disease 2781 (9.8) 2782 (9.9) 0.99
Coronary artery disease 6905 (24.5) 6943 (24.6) 0.714
Metastatic cancer 41 (0.1) 39 (0.1) 0.911
Liver disease 368 (1.3) 375 (1.3) 0.825
Aortic prosthesis
Bioprosthetic 16 954 (60) 16 961 (60.1) 0.958
Mechanical 11 324 (40.1) 11 313 (40.1) 0.931
Concomitant procedures, n (%)
Percutaneous coronary intervention 109 (0.4) 103 (0.4) 0.73
IABP/LV assist device use 549 (1.9) 529 (1.9) 0.557
Hospital characteristics, n (%)
Teaching hospital 19 207 (68) 19 207 (68) 0.99
Hospital bed size 0.617
Small 1874 (6.6) 1868 (6.6)
Medium 5075 (18) 5068 (17.9)
Large 21 288 (75.4) 21 301 (75.4)
Rural location 1012 (3.6) 1029 (3.6) 0.719
Nonelective admission status, n (%) 7957 (28.2) 7968 (28.2) 0.962
Primary payer, n (%) 0.165
Medicare/Medicaid 19 489 (69) 19 301 (68.4)
Private including HMO 7648 (27.1) 7818 (27.7)
Self-pay/no charge/other 1100 (3.9) 1118 (4)
Median household income, n (%) 0.866
0 to 25th percentiles 6257 (22.2) 6232 (22.1)
26th to 50th percentiles 7303 (25.9) 7342 (26)
51st to 75th percentiles 7357 (26.1) 7352 (26)
76th to 100th percentiles 7320 (25.9) 7311 (25.9)
AVR indicates aortic valve replacement; HMO, health maintenance organization; IABP, intra-aortic balloon pump; LV, left ventricular.
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higher in women compared with men following both combined
AVR (odds ratio: 1.4; 95% confidence interval [CI], 1.36–1.49;
P<0.0001) and isolated AVR (unadjusted odds ratio: 1.3; 95%
CI, 1.45–1.39; P<0.0001; adjusted odds ratio: 1.2; 95% CI,
1.07–1.29; P=0.001). The higher mortality rate in women was
consistent throughout the 12-year study period and was seen
among most subgroups of patients (Figure S2). Compared
with men, women had more vascular complications and blood
transfusions but similar rates of stroke, permanent
pacemaker implantation, and acute kidney injury requiring
dialysis. Although cost of hospitalization was similar, resource
utilization was higher for women because of the significantly
higher need for intermediate care or skilled nursing after
discharge (27.9% versus 19.6%, P<0.001). This could be
related to the higher incidence of vascular complications and
blood transfusions in women but also could be related to the
higher incidence of frailty among older women with AS.32
The discussion of our findings would be incomplete without
alluding to the emerging data demonstrating superior out-
comes of TAVR in women compared with men and a higher
magnitude of benefit of TAVR versus surgical AVR in women
than in men.1,14,24,33 A large report from the ACC/TVT
registry examined sex differences among 11 808 patients
who underwent TAVR and found no difference in in-hospital
mortality in women versus men after TAVR but significantly
better 1-year mortality in women versus men (adjusted hazard
ratio: 0.73; 95% CI, 0.63–0.85; P<0.001).14 Similarly, in a
patient-level meta-analysis including 11 310 patients, women
had similar mortality to men at 30 days but had significantly
better long-term survival (adjusted hazard ratio: 0.79; 95% CI,
0.73–0.86; P=0.001), despite higher rates of in-hospital
complications.1 A subgroup analysis of the PARTNER trial
showed that women who underwent TAVR had better short-
term (6.8% versus 13.1%; P=0.07) and long-term (hazard ratio:
0.67; 95% CI, 0.44–1.0; P=0.049) mortality compared with
women who underwent AVR.24 Likewise, a subgroup analysis
Figure 3. Trends of in-hospital mortality following isolated
surgical aortic valve replacement in men and women between
2003 and 2014.
Table 4. In-Hospital Outcomes of Propensity Score–Matched Patients Undergoing Isolated Surgical AVR Between 2003 and 2014
Male (n=28 237) Female (n=28 237) P Value
Clinical outcome, n (%)
In-hospital death 806 (2.9) 943 (3.3) 0.001
Procedural death 87 (0.3) 117 (0.4) 0.042
Vascular complications 1581 (5.6) 1705 (6) 0.027
Vascular complications requiring surgery 1178 (4.2) 1237 (4.4) 0.228
Permanent pacemaker implantation 1686 (6) 1769 (6.3) 0.15
Transient ischemic attack 108 (0.4) 81 (0.3) 0.059
Clinical stroke 682 (2.4) 682 (2.4) 0.99
Acute kidney injury 3881 (13.7) 2968 (10.5) <0.0001
Acute kidney injury requiring dialysis 404 (1.4) 363 (1.3) 0.144
Blood transfusion 9563 (33.9) 11 386 (40.4) <0.0001
Cardiac tamponade 267 (0.9) 209 (0.7) 0.009
Discharge status, n (%) <0.0001
Discharged home 21 831 (77.3) 19 342 (68.5)
Discharged SNF/NH/IC 5545 (19.6) 7882 (27.9)
Length of stay, d, median (IQR) 7 (6) 7 (6) <0.0001
Cost of hospitalization, $, mean (SD) 49 774 (34 701) 50 111 (24 372) 0.248
AVR indicates aortic valve replacement; IC, intermediate care; IQR, interquartile range; NH, nursing home; SNF, skilled nursing facility.
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of the pivotal CoreValve trial showed superior 1-year survival
in women who underwent TAVR versus those who underwent
AVR (12.7% versus 21.8%; P=0.03).33 It is worth noting that in
this study, we found that 28% of isolated AVRs were
performed during nonelective admissions (Table 3). Isolated
AVR during a nonelective admission is associated with
a 43% increase in cost ($217 660187 318 versus
$151 817124 094, P<0.001). Further studies are needed
to assess the impact of procedural status (elective versus
nonelective) on cost of AVR in the TAVR era.
Limitations
This study has a number of limitations. First, the NIS is an
administrative database that aims to gather data for billing
purposes and can be limited by erroneous coding; however,
the HCUP quality control measures should minimize these
possibilities. Furthermore, the hard clinical end points used in
our analysis are difficult to miscode. Second, the NIS allows
detailed assessment of in-hospital outcomes; however,
certain laboratory and echocardiographic data as well as
some procedural details such as aortic valve gradient, valve
size, and ejection fractions are not captured. In addition,
long-term mortality data are unavailable in this database.
Third, the potential for unmeasured confounders may bias
the outcome results in the propensity score–matched
cohorts; however, we believe that our rigorous propensity
matching and the sensitivity analysis adequately addressed
this selection bias.
Conclusion
In a contemporary nationwide analysis, AVR is performed less
often in women then in men. Women also have worse in-
hospital mortality and are more likely to be discharged to a
nursing home or intermediate care facility compared with
men. These data, coupled with the accumulating evidence
suggesting superiority of TAVR over AVR in women, under-
score the need for a rigorous controlled trial specifically in
female patients to properly study mortality differences
between treatment modalities.
Disclosures
None.
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Table S1. Variable Used for Propensity Score Matching 
  
Age 
Race 
Hypertension 
Hyperlipidemia 
Diabetes mellitus without complications 
Diabetes mellitus with complications  
Congestive heart failure 
Chronic kidney disease 
Peripheral vascular disease 
Pulmonary hypertension  
Hypercoagulable state 
Obesity 
Coronary artery disease  
Valvulopathy 
Electrolyte abnormalities 
Conduction abnormality 
Coronary artery disease 
Percutaneous intervention 
Intraaortic balloon pump  
Atrial fibrillation\flutter 
Blood loss anemia  
Iron deficiency anemia  
Paralysis 
Neurological disorders 
Chronic lung disease 
Hypothyroidism 
Liver disease 
AIDS* 
Lymphoma 
Metastatic disease 
Solid tumors without metastasis  
Collagen vascular disease  
Weight loss 
Alcoholism  
Depression 
Drug abuse  
Psychosis 
Hospital teaching status 
Admission Status 
Prior sternotomy 
 
* Acquired immunodeficiency syndrome
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Table S2. Characteristics of Patients Undergoing Isolated Surgical Aortic 
Valve Replacement Between 2003-2014 
 
Characteristic 
All Patients 
(n=85975) 
Male  
(n=52264) 
Female 
(n=33711) P value 
Age- mean (SD), y 66 (15) 64 (15) 69 (14) <0.0001 
Race- no. (%)  <0.0001 
   Caucasian 71994 (83.7) 43686 (83.6) 28308 (84) 
    African American 4440 (5.2) 2613 (5) 1827 (5.4) 
   Hispanic 5086 (5.9) 3300 (6.3) 1786 (5.3) 
Medical Comorbidity- no (%)  
   Hypertension 54850 (63.8) 32508 (62.2) 22342 (66.3) <0.0001 
   Diabetes 19907 (23.2) 11566 (22.1) 8341 (24.7) <0.0001 
   Prior Sternotomy 4701 (5.5) 3716 (7.1) 985 (2.9) <0.0001 
   Chronic Pulmonary Disease 16595 (19.3) 9473 (18.1) 7122 (21.1) <0.0001 
   Atrial Fibrillation/Flutter 34508 (40.1) 20819 (39.8) 13689 (40.6) 0.024 
   Cardiogenic Shock 2232 (2.6) 1405 (2.7) 827 (2.5) 0.034 
   Anemia 15502 (18) 8750 (16.7) 6752 (20) <0.0001 
   Coagulopathy 18909 (22) 11633 (22.3) 7276 (21.6) 0.02 
   Conduction Abnormalities 2900 (3.4) 1840 (3.5) 1060 (3.1) 0.003 
   Peripheral Vascular Disease 15633 (18.2) 10458 (20) 5175 (15.4) <0.0001 
   Chronic Renal Disease  9106 (10.6) 5982 (11.4) 3124 (9.3) <0.0001 
   Coronary Artery Disease 22035 (25.6) 14043 (26.9) 7992 (23.7) <0.0001 
   Metastatic Cancer 147 (0.2) 107 (0.2) 40 (0.1) 0.003 
   Liver Disease 1383 (1.6) 947 (1.8) 436 (1.3) <0.0001 
Aortic Prosthesis   
    Bioprosthetic 50371 (58.6) 29923 (57.3) 20448 (60.7) <0.0001 
   Mechanical  35713 (41.5) 22407 (42.9) 13306 (39.5) <0.0001 
Concomitant Procedures- no (%)  
   Percutaneous Coronary Intervention 298 (0.3) 184 (0.4) 114 (0.3) 0.735 
   IABP*/LV† Assist Device Use 1851 (2.2) 1260 (2.4) 591 (1.8) <0.0001 
Hospital characteristics- no (%)  
   Teaching Hospital 59215 (68.9) 36449 (69.7) 22766 (67.5) <0.0001 
   Hospital bed size  0.485 
         Small 5597 (6.5) 3360 (6.4) 2237 (6.6) 
 
         Medium  15477 (18) 9421 (18) 6056 (18) 
         Large 64901 (75.5) 39483 (75.5) 25418 (75.4) 
   Rural location  3065 (3.6) 1862 (3.6) 1203 (3.6) 0.964 
Non-elective Admission Status- no (%) 24447 (28.4) 15079 (28.9) 9368 (27.8) 0.001 
Primary Payer- no (%)  <0.0001 
   Medicare / Medicaid 53337 (62) 29136 (55.7) 24201 (71.8) 
 
   Private including HMO 28513 (33.2) 20184 (38.6) 8329 (24.7) 
   Self-pay/No charge/Other 4125 (4.8) 2944 (5.6) 1181 (3.5) 
Median Household Income- no (%)    <0.0001 
   1. 0-25th percentile 18411 (21.4) 10794 (20.7) 7617 (22.6) 
 
   2. 26-50th percentile 21939 (25.5) 13073 (25) 8866 (26.3) 
   3. 51-75th percentile 22387 (26) 13700 (26.2) 8687 (25.8) 
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* Intra-aortic balloon pump 
† Left ventricular
 
  
   4. 76-100th percentile 23238 (27) 14697 (28.1) 8541 (25.3) 
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 Table S3. In-Hospital Outcomes of Patients Undergoing Isolated Surgical 
Aortic Valve Replacement Between 2003-2014 
 
 
* Skilled nursing facility 
† Nursing home 
‡ Intermediate care
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 All Patients 
(n=85975) 
Male  
(n=52264) 
Female 
(n=33711) P value 
Clinical Outcome- no (%)  
   In-Hospital Death 2512 (2.9) 1404 (2.7) 1108 (3.3) <0.0001 
   Procedural Death 284 (0.3) 158 (0.3) 126 (0.4) 0.075 
   Vascular Complications 5143 (6) 3176 (6.1) 1967 (5.8) 0.144 
   Vascular Complications Requiring Surgery 3912 (4.6) 2502 (4.8) 1410 (4.2) <0.0001 
   Permanent Pacemaker Implantation 5169 (6) 3072 (5.9) 2097 (6.2) 0.039 
   Transient Ischemic Attack 273 (0.3) 170 (0.3) 103 (0.3) 0.616 
   Clinical Stroke 2056 (2.4) 1257 (2.4) 799 (2.4) 0.743 
   Acute Kidney Injury  10456 (12.2) 6854 (13.1) 3602 (10.7) <0.0001 
   Acute Kidney Injury Requiring Dialysis  1175 (1.4) 750 (1.4) 425 (1.3) 0.032 
   Blood Transfusion 31196 (36.3) 17470 (33.4) 13726 (40.7) <0.0001 
   Cardiac Tamponade 758 (0.9) 502 (1) 256 (0.8) 0.002 
Discharge Status- no (%)  <0.0001 
   Discharged Home 64659 (75.2) 42117 (80.6) 22542 (66.9) 
    Discharged SNF*/NH†/IC‡ 18631 (21.7) 8651 (16.6) 9980 (29.6) 
Length of Stay- mean (SD), d 10 (9) 9 (900) 10 (900) <0.0001 
Cost of hospitalization- mean (SD), $ 50074 (34799) 50137 (35334) 49975 (33953) 0.504 Dow
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Table S4. Summary of the Literature on Gender Disparity Following Surgical 
and Transcatheter Aortic Valve Replacement 
 
Combined Surgical AVR* and CABG† 
Author, Year # Patients (F) Settings Results Conclusions 
Arank1i et al. 
1993 
717  
(326) 
Single Center, 
Retrospective 
30-day mortality:  
M‡: 5.6% AVR vs 7.4% AVR+CABG (p=0.31)  
F§: 2.9% AVR vs 10.3% AVR+CABG (p=0.006) 
Short term Mortality better in 
females after isolated AVR but 
worse after AVR/CABG 
Morris2 et al. 
1994 
1012 
 (329) 
Single Center, 
Retrospective 
Combined AVR+ CABG:  
30-day mortality: 6% F, 2% M (p<0.02). 
5-year mortality: 23% F, 17% M (p<0.02). 
Short and long term mortality worse 
in females. 
Ibrahim3 et al. 
2003 
1570  
(497) 
Single Center, 
Retrospective 
In-hospital mortality: 
Isolated AVR: 2.3% F vs. 1.7% M (p=NS) 
Combined AVR/CABG 7% F vs. 4% M (p=0.02).  
Short-term mortality similar for 
isolated AVR but worse in females 
after combined AVR+CABG. 
Doenst4 et al. 
2006 
1567  
(496) 
Single Center, 
Retrospective 
Combined AVR+ CABG:  
30-day mortality: 7% in F vs. 4% in M (p=0.026). 
5-yr survival rate: 77% F vs 78% M (p= 0.062). 
10-yr survival rate:  50% F vs 56% M (p= 0.062). 
Short-term mortality worse in 
females in combined AVR+CABG 
but long term mortality similar 
Isolated Surgical AVR 
Author, Year # Patients (F) Settings Results Conclusions 
Hanssen5 et 
al. 1999 
195 
(99) 
Single Center, 
Prospective 
30-day mortality:  
5.6% F vs. 3.1% M (p=0.229). 
Similar short term mortality 
(underpowered) 
Duncan6 et 
al. 2006 
2212 
(782) 
Single Center, 
Retrospective 
In-hospital mortality:  
Unadjusted 3.5% F vs. 1.6% M (p=0.005) 
Adjusted 3.9% F vs. 3.9% M (p=0.99) 
Similar short term mortality 
Caballero-
Borrego7 et 
al. 2009 
577 
(254) 
Single Center, 
Retrospective 
In-hospital mortality:  
Unadjusted 13% F vs. 7.4% M (p=0.019) 
Adjusted HR in F 2.5 (CI 0.79-7.26, P=0.12) 
Similar short term mortality 
Hamed8 et al. 
2009 
406 
(183) 
Single Center, 
Retrospective 
30-day mortality: 3.4% overall with no difference 
between F and M 
Similar short term mortality 
Kulik9 et al. 
2009 
3118  
(1261) 
Single Center, 
Retrospective 
10-yr actuarial survival rate: 
Bioprosthetic AVR: 70% F vs. 55.9% M (p<0.001).  
Mechanical AVR: 79.1% F vs. 73.3% (p=0.74). 
Long term mortality better in 
females only in bioprosthetic AVRs 
Fuchs10 et al. 
2010 
408 
(215) 
Single Center, 
Retrospective 
1,2,5 years actuarial survival rates: 92.8%, 89.8%, 
81.4% F vs. 89.1%, 86.6%, 76.3% M (p=0.31) 
Similar short term mortality 
Elhmidi11 et 
al. 2014 
2197 
(907) 
Single Center, 
Retrospective 
30-day mortality: 4.4% F vs. 1.6% M (p<0.001) 
1-yr mortality: 13% F vs. 9.6% M (p=0.04) 
Short and long term mortality worse 
in females 
Transcatheter AVR 
Author, Year # Patients (F) Settings Results Conclusions 
Buchanan12 
et al. 2011 
305 
(146) 
Single Center, 
Retrospective 
30-day mortality following TAVR: 
 4.7% F vs. 4.7% M (p=0.99)  
Similar short term mortality 
Humphries13 
et al. 2012 
641 
(329) 
Multicenter, 
Retrospective 
30-day mortality:   
6.5% F, 11.2% M (p=0.05). 
Better short term mortality in 
females 
Hayashida14 
et al. 2012 
260 
(131) 
Single Center, 
Prospective 
30-day mortality: 12.2% F, 17.8% M (p=0.207) 
1-yr mortality: (HR 1.62, CI 1.03-2.53, p=0.037) 
Similar short term but better 1-yr 
mortality in females 
Zhao15 et al. 
2013 
9118 
(4942) 
Meta analysis 
(through April 
2013) 
30-day mortality:   
Higher in males (HR 1.37, 95% CI 1.07-1.76). 
1-yr mortality:  
Higher in males (HR 1.30, 95% CI 1.14-1.49). 
Short and long term mortality better 
in females 
Conrotto16 et 
al. 2014 
836 
(464) 
Multicenter, 
Retrospective 
30-day mortality: 6.5% F, 5.6% M (p=0.62) 
1-yr mortality: 18.1% F, 22.6% M (p=0.11) 
Similar short and long term 
mortality 
Stangl17 et al. 
2014 
7973 
 (4242) 
Meta analysis 
(through June 
2014) 
30-day mortality: Lower in F (HR 0.78, CI 0.64-0.96) 
Long-term mortality: Lower in F (HR 0.70, CI 0.59, 
0.82) 
Short and long term mortality better  
in females 
Erez18 et al.  
2014 
224 
(127) 
Single Center, 
Retrospective 
30-day mortality: 4% F, 5% M (p=0.45). 
 
Similar short term mortality 
Williams19 et 
al. 2014 
699 
(300) 
Multicenter, 
Prospective 
2-yr mortality:  
In F, 28.2% TAVR vs. 38.2% SAVR (p=0.049) 
In M, 37.7% TAVR vs. 32.3% SAVR (p=0.42) 
Long term survival benefit for 
female but not for males with TAVR 
D
ow
nloaded from
 http://ahajournals.org by on April 7, 2020
 
* Aortic Valve Replacement. 
† Coronary Artery Bypass Grafting. 
‡ Female 
§ Male
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Biere20 et al  
2015 
3972 
(1967) 
National 
Registry 
30-day mortality: 9.5% in F vs. 9.2% in M (p=0.27) 
1-yr mortality: 19.3% in F vs. 23.7% in M (p=0.021) 
Long term survival better in 
females than males after TAVR 
Chandrasekh
ar21 et al 
2016 
23652 
(11808) 
National 
Registry 
1-yr mortality: 21.3% in F vs. 24.5% in M  
(Adjusted HR: 0.73; 95% CI: 0.63 to 0.85; p < 0.001)  
Long term survival better in 
females than males after TAVR  
Kodali22 et al  
2016 
2559 
(1220) 
Multicenter, 
Prospective 
30-day mortality: 6.5% in F vs. 5.9% in M (p=0.52) 
1-yr mortality: 19% in F vs. 25.9% in M (p<0.001) 
Similar short term mortality but 
better long term survival in females  
Czarnecki23 
et al 2017 
999 
(453) 
Multicenter, 
Retrospective 
30-day mortality: 7.2% in F vs. 5.4% in M (p=0.34) 
1-yr mortality: 18.2% in F vs. 19.2% in M (p=0.85) 
Similar short term and long term 
mortality  
D
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Figure S1. Standardized mean differences before and after propensity Score Matching. 
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Figure S2. Subgroup Analysis of Sex Disparity in In-Hospital Mortality Following 
Isolated Surgical Aortic Valve Replacement (male used as a reference group). 
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Figure S3. Sensitivity Analysis for Required Strength of an Unmeasured Confounder. 
Each line splits the area into two: The upper right corner of the graph above the 
confines of a line represents all parameter combinations of an association between an 
unmeasured confounder to the treatment (AVR in female patients; y axis) and the 
outcome (blood transfusion; x axis) required to move the measured OR to null. 
Conversely, the lower left corner represents all parameter combinations of an 
association between an unmeasured confounder to the treatment and outcome that 
would not move the measure OR to null. 
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Figure S4. Proportion of TAVR and SAVR among Males and Females who underwent aortic valve replacement since 
commercial approval of TAVR. (TAVR; transcatheter aortic valve replacement, SAVR; surgical aortic valve replacement.) 
 
 
 
D
ow
nloaded from
 http://ahajournals.org by on April 7, 2020
